Kazuya Kariyama

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis

Atsushi Hiraoka, Takashi Kumada, Kunihiko Tsuji et al. · Liver Cancer · 2018 · 230 citations · Full text

Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications

Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo et al. · Liver Cancer · 2017 · 208 citations · Full text

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa et al. · Cancer Medicine · 2019 · 158 citations · Full text

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama et al. · Cancer Medicine · 2018 · 130 citations · Full text

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima et al. · ESMO Open · 2022 · 124 citations · Full text